Apigenin synergizes with Abivertinib to inhibit the proliferation of diffuse large B-cell lymphoma via down-regulating PI3K/p-AKT/p-IKK/p-P65 signal pathway. Here, AKT1 is linked to diffuse large B-cell lymphoma.